WUXI BIO (02269) announces its performance for 2025: record high net profit of 4.9 billion yuan.

WUXI BIO(02269) announces its 2025 performance, with both revenue and net profit seeing a significant year-on-year increase, reaching a historical high. Revenue is 21.8 billion yuan, a year-on-year growth of 16.7%; net profit attributable to shareholders is 4.9 billion yuan, a year-on-year growth of 46.3%. Gross profit is 10 billion yuan, a year-on-year growth of 30.9%; gross profit margin is 46%, a year-on-year growth of 5 percentage points. In 2025, the three major high-growth molecular types drove the company to achieve a historical high in new contract projects. There were 209 new contract projects, with 2/3 of them being bispecific antibodies and Antibody-Drug Conjugates (ADC). The total number of projects is 945, with over 50% being complex molecular projects. Bispecific/multispecific antibody projects have become the company's core growth engine, contributing to a year-on-year revenue growth of 120%. In the company's CRDMO services business, the research business saw historical highs in upfront and total payment amounts, enhancing profit capabilities. The total potential milestone payment amount for research collaboration projects exceeded 4 billion US dollars. In the development business, the company supported 156 IND applications within the year, with new development projects reaching a new high, with bispecific/multispecific antibodies and ADC projects growing by approximately 30%. In the production business, the company served 74 Phase III clinical projects and 25 commercial production projects, completing 28 Process Performance Qualification (PPQ) projects, a year-on-year growth of 75%. In 2026, there are already scheduled 34 PPQ projects, and the commercial production business is expected to accelerate growth.